Dr. William W. Stringer, M.D.
Pulmonology (Pulmonary Disease Physician)
1124 W Carson St
Torrance, CA 90502
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- University of California, San Diego School of Medicine (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
Licensed in California since 1985, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: University of California, San Diego School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
CA license G55175 (first issued 1985; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Prohealth PArtners, A Medical Group (239 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 5 companies reported 8 payments worth $3,406 in total to this clinician.
| Verona Pharma, Inc. | $1,800 |
|---|---|
| Prolaio, Inc. | $1,500 |
| Merck Sharp & Dohme LLC | $63.84 |
| Pfizer Inc. | $26.46 |
| Paratek Pharmaceuticals, Inc. | $15.59 |
| Consulting Fee | $3,300 |
|---|---|
| Food and Beverage | $106 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Verona Pharma, Inc. Jul 29, 2025 | Consulting Fee Ohtuvayre · Pulmonary/Respiratory Diseases | $1,800 |
| Prolaio, Inc. Mar 27, 2025 | Consulting FeeCompany’s descriptionPayment related to Prolaio Heart Rhythm and Respiratory Module | $1,000 |
| Prolaio, Inc. Oct 9, 2025 | Consulting FeeCompany’s descriptionPayment related to Prolaio Heart Rhythm and Respiratory Module | $500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $248,928 in research payments for these studies, mostly to the institutions running them.
- A Double Blind,Multicentre,Randomized,Three Period,Three Treatment,CrossOver Study to Evaluate the Effect of BGF MDI,BFF MDI,and Placebo MDI on Exercise Parameters in Participants with Chronic Obstructive Pulmonary Di…
AstraZeneca UK Limited - Observational, Non-Interventional Study Supporting Validation of eVO2peak Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)
Prolaio, Inc. · Recruiting · NCT05678530 - Ph IIb of Astegolimab in COPD
Genentech, Inc. - Phase 2 Double Blind Randomized Study in IPF and SSc ILD
Genentech, Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
Galderma Laboratories, L.P. · Completed · NCT04921345
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.